On March 5, aiming at enhancing the core competitiveness of the manufacturing industry, the government work report of the State Council proposed to start a number of industrial infrastructure reconstruction projects, promote the upgrading of traditional industries, accelerate the development of advanced manufacturing clusters, and implement the national strategic emerging industry cluster project. Focus on cultivating “specialized and special new” enterprises, and give strong support in terms of capital, talents and incubation platform construction. Promote the construction of a quality power and promote the industry to move towards medium and high-end.
In fact, in order to implement the national development call of the 14th five year plan, all provinces, cities and regions will vigorously layout the construction of industrial clusters in 2021, among which the proportion of investment in biomedicine and health will increase, and several hundred billion or even trillion industrial clusters are expected to be put into construction in 2022. How to win opportunities in such a tuyere, the spotlight falls on “specialized and special new” enterprises.
Such enterprises are small and medium-sized, with about 500 people as the norm. Their business presents the characteristics of “specialization and innovation”. They focus on their main business, emphasize the breakthrough and practicability of their business, and have strong innovation vitality. These enterprises are used to running at the forefront of the industry and are more willing to explore new technologies and tools. They are an important part of China’s industrial foundation.
Specific to the fields of biomedicine and health, API enterprises belong to the category of “specialization and innovation”. They are located in the upper middle reaches and walk at the forefront of the pharmaceutical field. For example, yinuorui biological is the main manufacturer of heparin API in China, and heparin is an API widely used in antithrombotic and anticoagulant drugs, which is the first choice of anticoagulant drugs in clinic. With outstanding achievements in the field of heparin, in 2021, yinorui won the honor of the first batch of provincial specialized special new “little giant” enterprises in Hubei Province, and its heparin production capacity is expected to reach 360 million yuan in the same year.
Nori continues to be in the leading position in the pharmaceutical industry in terms of raw material and molecular extraction of heparin through the pharmaceutical chain with a total of 100 million patents. With the help of capacity expansion, it can compete with international companies such as Pfizer, SPL, Sanofi and bioiberica in overseas markets.
Another area closely related to API is pharmaceutical excipients, which are like seasonings in cooking. Although they are used less in pharmaceutical preparations, they can play a key role in activating efficacy. How to make the raw materials and excipients complement each other in the preparation process? The leading enterprises in the field of pharmaceutical excipients in China look forward to the pharmaceutical industry and launched customized services for pharmaceutical excipients. By benchmarking the product segmentation process of international standards, the “one-to-one” accurate docking of pharmaceutical preparations has been realized, and a new ecology of subdivided fields has been constructed.
So far, the prospect pharmaceutical products have covered nearly 3000 pharmaceutical enterprises in China, and are exported to more than 20 countries such as Europe, Russia, the United States and Japan, involving more than 10 varieties and more than 200 customer enterprises. They have occupied an important position in the raw and auxiliary material market outside China.
The scientific and technological innovation presented by yinuorui biology and prospect pharmaceutical industry is the cornerstone of innovation in the pharmaceutical field. Behind its success is the strong support of the parent company Tianjin Chase Sun Pharmaceutical Co.Ltd(300026) as the “chain owner” enterprise. In the context of the reshaping of the global industrial chain and supply chain, the “specialized and special” enterprises in the industrial chain are like scattered pearls, which can bloom brightly only when they are strung into a chain. In the process of enterprise development, Tianjin Chase Sun Pharmaceutical Co.Ltd(300026) formulated the development mode of the whole industrial chain, and effectively strengthened and integrated the upstream and downstream chain nodes through multiple advantages such as capital and industrial transformation experience.
Under this mode, the traditional industrial chain forms a community industrial chain, and forms a production network with “specialization and innovation” as the node. Compared with the traditional industrial chain form of upstream, middle and downstream, the relationship between enterprises is closer and more complex, the location of industrial chain is not obvious, and the boundary of division of labor is fuzzy. This model is conducive to improving the toughness of the industrial chain and building a digital economy ecosystem of symbiosis and common prosperity.
At present, Tianjin Chase Sun Pharmaceutical Co.Ltd(300026) has gathered a group of “little giants” of medicine, forming a whole industry chain matrix across multiple sectors Tianjin Chase Sun Pharmaceutical Co.Ltd(300026) the business model has also changed from the single line output of Xuebijing to the three arrows of finished drugs, traditional Chinese medicine formula particles and medical devices with Xuebijing as the core. Then, promote the layout of raw and auxiliary materials to the upstream and carry out the medical services of shangyirenjia to the downstream. Coupled with the introduction of the intelligent supply chain model of medicine and machinery, six carriages are driving hand in hand, forming a model of industrial innovation in the era of digital economy.
